Atrion (NASDAQ:ATRI) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.
Separately, ValuEngine upgraded Atrion from a “hold” rating to a “buy” rating in a research note on Monday, February 4th.
NASDAQ:ATRI opened at $826.50 on Thursday. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of 44.10 and a beta of 0.43. Atrion has a 12-month low of $560.65 and a 12-month high of $830.54.
Atrion Company Profile
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Featured Story: What is a stock buyback?
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.